Evidence map›Paper›PMID 38280036›Full record

ArticleCellular and molecular life sciences : CMLS2024

Functional role of Ash2l in oxLDL induced endothelial dysfunction and atherosclerosis.

Zhenghua Su, Jinghuan Wang, Chenxi Xiao, Wen Zhong, Jiayao Liu, Xinhua Liu, Yi Zhun Zhu

Open access · goldAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Zhenghua SuSchool of Pharmacy, Human Phenome Institute, Fudan University, Shanghai, 201203, China.
Jinghuan WangSchool of Pharmacy, Human Phenome Institute, Fudan University, Shanghai, 201203, China.
Chenxi XiaoSchool of Pharmacy, Human Phenome Institute, Fudan University, Shanghai, 201203, China.
Wen ZhongSchool of Pharmacy, Human Phenome Institute, Fudan University, Shanghai, 201203, China.
Jiayao LiuSchool of Pharmacy, Human Phenome Institute, Fudan University, Shanghai, 201203, China.
Xinhua LiuSchool of Pharmacy, Human Phenome Institute, Fudan University, Shanghai, 201203, China. liuxinhua@fudan.edu.cn.ORCID http://orcid.org/0000-0002-9972-8215
Yi Zhun ZhuSchool of Pharmacy, Human Phenome Institute, Fudan University, Shanghai, 201203, China. yzzhu@must.edu.mo.
Fudan University · CNMacau University of Science and Technology · MO

Funding

Science and Technology Commission of Shanghai Municipality 22S1190270Shanghai Municipal Science and Technology Major Project 2023SHZDZX02
6 · The paper itself

Abstract

Endothelial injury and dysfunction in the artery wall fuel the process of atherosclerosis. As a key epigenetic regulator, Ash2l (Absent, small, or homeotic-Like 2) is involved in regulating vascular injury and its complications. However, the role of Ash2l in atherosclerosis has not yet been fully elucidated. Here, we found increased Ash2l expression in high-cholesterol diet-fed ApoE

Indexed as

AtherosclerosisEndothelial CellsAnimalsApolipoproteins ELipoproteins, LDLMiceNF-kappa BReceptors, ScavengerApolipoproteins ELipoproteins, LDLNF-kappa Boxidized low density lipoproteinReceptors, ScavengerAsh2lAtherosclerosisEndothelial cellsNF-κBPPARγScavenger receptors

Identifiers

PMID38280036
PMCPMC10821849
OpenAlexW4391275404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.